HF
ENSC icon

HRT Financial’s Ensysce Biosciences ENSC Stock Holding History

HRT Financial’s Portfolio ENSC Stock Details ENSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-24,491
Closed -$22K – 4031
2025
Q4 		$22K Buy
+24,491
New +$45.5K ﹤0.01% 2971
2024
Q4 		– Sell
-1,571
Closed -$5K – 2610
2024
Q3 		$5K Buy
+1,571
New +$9.53K ﹤0.01% 2266

Other funds holding ENSC

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
TIAM2
Tru Independence Asset Management 2 Portland, Oregon $163M AUM 18.06% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

HRT Financial's ENSC Position: Q1 2026 in Review

HRT Financial sold out of Ensysce Biosciences (ENSC) in Q1 2026, closing a stake of 24,491 shares — an estimated $22K sold.

HRT Financial first reported a position in ENSC in Q3 2024 and held it in 2 quarters. The position peaked at $22K in Q4 2025. 15 funds tracked by Wall St. Rank hold ENSC as of Q1 2026.

  • HRT Financial reported no remaining Ensysce Biosciences position as of Q1 2026 after selling out during the quarter.
  • HRT Financial sold 24,491 Ensysce Biosciences shares in Q1 2026, an estimated $22K.
  • HRT Financial first reported a position in Ensysce Biosciences in Q3 2024 and held it in 2 quarters.
  • HRT Financial's Ensysce Biosciences position peaked at $22K in Q4 2025.
  • 15 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.